Shenzhen Boya Gene Technology Co., Ltd. is a biotechnology startup focused on the research and clinical translation of gene therapy drugs, with a focus on chronic diseases and functional degenerative diseases that seriously affect the health of a large number of elderly people. Our gene drug uses adenovirus associated virus (AAV) as a delivery technology. And apply the achievements of cutting-edge biotechnology such as Synthetic Biology, Directed Evolution, and Machine Learning in recent years to the design and production of AAV, developing it into the "IDEAL-AAV-DOS" platform. This platform comprehensively optimizes the disease-specific target cell selectivity, production and manufacturing costs, and human immunogenicity of AAV to obtain the global optimal solution, enabling gene therapy drugs to improve efficacy and safety while reducing costs and being applied to a large number of patients. The successful development of this system can not only accelerate and reduce costs for our self-developed drug projects, but also provide contract development (CRO) and contract manufacturing services (CDMO) for AAV for cooperative enterprises or researchers.